Nuvalent (NUVL) Other Non Operating Income (2020 - 2026)
Nuvalent's (NUVL) quarterly Other Non Operating Income came in at -$2.6 million in Q1 2026, down 79.72% YoY from -$12.7 million in Q1 2025, and down 109.38% on a QoQ basis from $27.4 million in Q4 2025.
Analysis
Nuvalent (NUVL) Other Non Operating Income (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 6 years of Other Non Operating Income data on file, last reported at -$2.6 million in Q1 2026.
- Quarterly Other Non Operating Income fell 79.72% year-over-year to -$2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 million (up 94.7% YoY) and the FY2025 annual result came in at $113000.0, up 100.63% from the prior year.
- Other Non Operating Income eased to -$2.6 million in Q1 2026, from $27.4 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $27.4 million in Q4 2025 to a low of -$19.8 million in Q3 2025.
- A 4-year average of -$1.9 million and a median of -$1.3 million in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 67100.0% in 2022, down 1311.24% in 2022.
- Tracing NUVL's Other Non Operating Income over 4 years: stood at -$1.1 million in 2022, then slipped by 24.3% to -$1.3 million in 2024, then soared by 2144.25% to $27.4 million in 2025, then tumbled by 109.38% to -$2.6 million in 2026.
- The last three Other Non Operating Income figures came in at -$2.6 million (Q1 2026), $27.4 million (Q4 2025), and -$19.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -2.57 Mn |
| Dec 31, 2025 | -27.94 Mn |
| Sep 30, 2025 | -19.81 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -1.43 Mn |
| Dec 31, 2024 | -1.34 Mn |
| Sep 30, 2024 | -16.60 Mn |
| Dec 31, 2022 | -1.08 Mn |
| Sep 30, 2022 | 672,000.00 |
| Jun 30, 2022 | 267,000.00 |
| Mar 31, 2022 | 139,000.00 |
| Dec 31, 2021 | 89,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 12,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | -3,000.00 |
| Sep 30, 2020 | -14,000.00 |
| Jun 30, 2020 | -9,000.00 |